Temodal 5 mg hard capsules
Sponsors
Inhibrx Biosciences Inc., TME Pharma AG, Laminar Pharmaceuticals S.A., Institut Gustave Roussy, Renaissance Pharma Limited
Conditions
Advanced or metastatic solid tumorsGlioblastomaNewly diagnosed primary glioblastoma multiforme (ndGBM)Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resectedParticipants with relapsed HRNB and participants
with HRNB refractory to treatment
The clinical trial will recruit participants aged ≥18 months to <18 yearsand therefore all participants will be minors at the time of consent.
Phase 1
Single-arm dose-escalation Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter with a multiple-arm expansion group
RecruitingCTIS2024-510964-21-00
Start: 2019-09-12Target: 136Updated: 2025-11-18
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas.
RecruitingCTIS2023-508139-29-00
Start: 2024-06-26Target: 37Updated: 2025-10-09
Phase 2
A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment.
Active, not recruitingCTIS2024-511542-39-00
Start: 2019-09-16Target: 106Updated: 2025-10-01
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Not yet recruitingCTIS2025-524397-42-00
Target: 47Updated: 2026-06-30